Watchlist Price Alert

AnaptysBio Inc. (ANAB)

NASDAQ: ANAB · Real-Time Price · USD

19.61

0.03 (0.15%)

At close: May 09, 2025, 3:59 PM

19.70

0.46%

After-hours: May 09, 2025, 04:48 PM EDT

0.15% (1D)

Bid	18
Market Cap	576.15M
Revenue (ttm)	91.28M
Net Income (ttm)	-145.23M
EPS (ttm)	-4.76
PE Ratio (ttm)	-4.12
Forward PE	-3.95
Analyst	Buy

Ask	22
Volume	367,372
Avg. Volume (20D)	1,021,062
Open	19.57
Previous Close	19.58
Day's Range	19.09 - 20.04
52-Week Range	12.21 - 41.31
Beta	-0.20

About ANAB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ANAB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ANAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

AnaptysBio has released their quartely earnings on May 5, 2025:

Revenue of $27.77M exceeds estimates by $12.5M, with 286.84% YoY growth.

EPS of -1.28 exceeds estimates by 0.18, with 21.95% YoY growth.

Why Price Moved

1 month ago

+9.54%

AnaptysBio shares are trading higher after the com... Unlock content with Pro Subscription

2 months ago

+30.45%

AnaptysBio shares are trading higher after the company announced statistically significant week 12 data from the Phase 2b trial of rosnilimab in moderate-to-severe rheumatoid arthritis.

News

4 days ago · zacks.com

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1.64 per share a year ago.

1 month ago · zacks.com

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

2 months ago · zacks.com

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.

2 months ago · zacks.com

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

2 months ago · zacks.com

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in...